A Phase 1, Open-Label, Randomized-Sequence, Single-Crossover, Bridging Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Two ND-L02-s0201 Formulations, Frozen Versus Lyophilized, Administered by Intravenous Infusion to Healthy Male and Female Subjects
Latest Information Update: 05 Nov 2021
At a glance
- Drugs BMS-986263 (Primary)
- Indications Fibrosis; Hepatic fibrosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb; Nitto Denko
- 09 Aug 2017 New trial record